Pharma intelligence for marketing agencies
Gain insight into the pharmaceutical market landscape – we’ll help you communicate complex ideas clearly and develop customer-centric propositions.
With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. As a marketer, you have to engage with multiple audiences across a variety of channels and to communicate complex information simply and persuasively.
We give you the means to identify future innovation and new market opportunities, develop customer-centric propositions, and keep a close eye on competitors. We can also help with branding, multi-channel communication and more.
What we offer
As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our pharma intelligence will help you build a complete picture of the market and get access to past, current and future trends and analysis.
How it helps
You’ll get cutting-edge insights on the size and shape of markets, competitive threats, actionable customer perceptions and industry innovations.
Our accurate, reliable intelligence will help you:
The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.
Key benefits:
A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.
Key benefits:
Unparalleled access to global pharma regulatory and compliance intelligence and expertise.
Key benefits:
Michael McCaughan 16 Jun 2022
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.
13 May 2022
Join Informa Pharma Intelligence for the “Global Oncology Opportunities” webinar!
Vibha Sharma 18 Jan 2022
The EU will make it mandatory for clinical trial sponsors to prepare layperson summaries of their study results. Industry practices around content presentation, translation and dissemination of these documents will be keenly watched.
Scrip Team 17 Jan 2022
Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.
Alaric DeArment 05 Jan 2022
The companies’ third vaccine-development deal shows how COVID cash has also led mRNA-focused companies to beef up their organic pipelines amid talk of a merger wave.
Generics Bulletin
01 Dec 2021
Bio-Thera Solutions had been hoping to become the first Chinese biosimilars developer to win an FDA approval, for its BAT1706 bevacizumab candidate. However, the announced FDA action date for the application has come and gone with no word from the company or regulator.
Scrip
16 Nov 2021
Having strongly made the case for Jardiance as a treatment for chronic heart failure, Boehringer Ingelheim and Eli Lilly believe the SGLT2 inhibitor could have a lot of potential in acute heart failure as well after promising data from the EMPULSE study.
Andrew McConaghie 12 Nov 2021
AstraZeneca is one of the sector’s top growth stories in 2021, but controversies around its COVID-19 vaccine continue to grab headlines, and Chinese price cuts bite.
Alaric DeArment 02 Nov 2021
The company increased its guidance for sales of the COVID-19 vaccine again, to $36bn, though many other products’ sales were close to or below analyst expectations.
Malcolm Spicer 31 Oct 2021
While working to improve the quality of VMS products available in the US and to provide information on the products to consumers, the ODS doesn’t have authority to impose change on the industry or in the marketplace.
Scrip
By Andrew McConaghie 19 Oct 2021
The VC firm is making the most of a surge of capital from new and established investors who believe in the promise of European biopharma start-ups.
12 Oct 2021
The company behind the CVnCOV COVID-19 vaccine candidate says the decision to withdraw from regulatory review is strategic. The EMA says outstanding issues affecting the benefit-risk balance remained to be answered at the time of withdrawal.
05 Oct 2021
With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.
01 Oct 2021
Merck/Ridgeback’s ribonucleoside analog shows nearly 50% reduction of risk for hospitalization or death in Phase III study. Firms will seek EUA in US; a contract is in place for 1.7 million courses of therapy.
17 Sep 2021
The EU’s creation of a Health Emergency Response Authority to deal with future health threats has been welcomed by off-patent industry association Medicines for Europe. However, the organization pointed out current policy and regulatory weaknesses that must be addressed if HERA is to be successful.
28 Jun 2022
28 Jun 2022
28 Jun 2022
Generics Bulletin
27 Jun 2022
27 Jun 2022
27 Jun 2022
Scrip
27 Jun 2022
27 Jun 2022
27 Jun 2022
27 Jun 2022
27 Jun 2022
HBW Insight
26 Jun 2022
Pink Sheet
25 Jun 2022
24 Jun 2022
24 Jun 2022
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: